CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Carboplatin +2 moredrug
Likely dose
Paclitaxel 175 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02513563
NCT02513563Phase 2Completed
CompareCT.gov

A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Jul 31, 2015·Updated Feb 19, 2026

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Paclitaxel, and 1 other intervention for Lung Cancer. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 31, 2015
Enrollment StartOct 13, 2015
Primary CompletionNov 27, 2022
Study CompletionNov 28, 2023
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 10.9 years ago

Interventions

Carboplatindrug

Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

Paclitaxeldrug

Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.

AZD1775drug

Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.